NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study

CompletedN/A

Sponsor: AstraZeneca

Conditions: COVID-19

Interventions: ChAdOx1 nCOV-19 vaccine (Vaxzeria), BNT162b2 (Pfizer), Ad26.COV2.S (Janssen), CoronaVac (Sinovac)

Countries: Brazil

This study will address specific questions concerning the additional protection of the AZ COVID-19 vaccine as a second booster dose in preventing severe COVID-19 outcomes (hospitalisation, ICU admission etc) and will provide data to inform COVID-19 vaccine booster dose recommendations.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Hospitalized for SARS between 01 January 2022 and 31 December 2022 (Population A) or hospitalised for SARS between 01 August 2021 and 31 December 2022 (Population B).
* Eligible for a second COVID-19 vaccine booster dose at the time of SARS hospitalization (i.e., aged 50+ or aged 18+ and either a HCW or with an IC) for second booster objectives \[Population A\] OR eligible for a first COVID-19 vaccine booster dose at the time of SARS hospitalisation (i.e., aged 18+) for first booster objectives \[Population B\].
* Results available for a RT-PCR and/or antigen test for SARS-CoV-2 conducted on a sample taken up to 14 days after symptom onset.
* Individuals have required matching variables (e.g. age and sex).

Exclusion Criteria:

* Hospitalized for COVID-19 within 3 months prior to date of current hospital admission for SARS
* Nosocomially-acquired infection (where SARS case is flagged as nosocomial and/or where symptom onset date is after hospitalisation date)

Locations (1)

São Paulo, Brazil